RheumNow Podcast – Falling or Falling in Love? Save

Dr. Jack Cush reviews the best journal articles from the past week on RheumNow.com.

1. Study of healthcare resource utilization and costs psoriasis, psoriatic arthritis (PsA) vs controls; PsA has the highest annual all-cause healthcare costs per patient - Controls =$7,470, Psoriasis= $11,062, and PsA = $29,742 https://t.co/06irRupcLJ
2. Falls are not uncommon in #RA patients; significant risk factors for falls include being elderly, un-married, higher pain scores, reported dizziness taking psychotropic medications and having lower HRQoL scores https://bit.ly/3t7yEJS
3. Belimumab now approved in the EU for lupus nephritis. The EMA has approved intravenous and subcutaneous Benlysta (belimumab) in combination with background immunosuppressive therapies for adults with active lupus nephritis https://t.co/Twbe1ClT5w
4. TNF inhibitor induced (paradoxical) psoriasis in JIA patients was 3 fold higher when TNFi was used - data from 8,222 children in the CARRA registry (54% used TNFi) - rate 8.5 cases/1000PY.https://t.co/HKpAEbtNqr  https://t.co/txvmGfpdWf
5. Nested case–control study from the Danish (DANBIO) Register and 8019 Psoriatic arthritis patients shows that pain alone does not influence mortality risk; however steroid and comorbidities do! https://t.co/74haeSXwXn
6. Risk factors for Kawasaki disease in Taiwan compared 4197 KD pts to controls. KD was more common in Males (OR 1.47), older mothers (>35 y; OR, 1.18), and in multivariable analysis, maternal ankylosing spondylitis (OR 2.02). https://t.co/4qbddaYkqY
7. Real world comparision of baricitinib (n 138) and tofacitinib (n 156) in #RA patients shows at wk 24, BARI out performed TOFA - CDAI remission (40.4 vs 28.3%) and CDAI LDA (81.6 vs 69.3%); safety signals were equal between groups. https://t.co/0quNNGB18K
8. Metanalysis of 9 studies, and 1132 lupus pregnancies shows that hydroxychloroquine treatment significantly reduced the risk of preeclampsia (OR 0.35), pregnancy hypertension (OR 0.41)and prematurity (OR 0.55), but no effect on rates of HELLP, DM, Ab rates https://t.co/P9MXjDpuiO
9. Childhood Lupus May Hamper Adult Careers 
10. Drug Monitoring Ineffective with Infliximab Treatment 
11. Uric Acid: A Major Player in the Metabolic Syndrome
12. BACK TALK 
13. TNR – last weeks replay of RNL 2021 on Psoriatic disease